Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KontRASt-06 first-line JDQ443 monotherapy in KRAS G12C-mutant advanced NSCLC
CTR20223456Phase 2Completed
- Sponsor
- Novartis
- Start
- Jun 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of opnurasib in non-small cell lung cancer (NSCLC), sponsored by Novartis. Started Jun 2023; status: completed.
02
Drugs
opnurasib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on CTR20223456.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20223456.